公开(公告)号：US20190106437A1

公开(公告)日：2019-04-11

申请号：US16094030

申请日：2017-04-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi KAWAKITA ,  Takuto KOJIMA ,  Noriyuki NII ,  Yoshiteru ITO ,  Nobuki SAKAUCHI ,  Hiroshi BANNO ,  Xin LIU ,  Koji ONO ,  Keisuke IMAMURA ,  Shinichi IMAMURA

IPC: C07D519/00 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

公开(公告)号：US20230117295A1

公开(公告)日：2023-04-20

申请号：US18075853

申请日：2022-12-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  C07D403/14 ,  C07D401/12 ,  C07D471/10 ,  C07D495/10 ,  C07D405/12 ,  C07D403/12 ,  C07D213/84 ,  C07D487/10 ,  C07D405/14 ,  A61P35/00

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20170037057A1

公开(公告)日：2017-02-09

申请号：US15304727

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masanori Okaniwa ,  Hiroshi BANNO ,  Takaharu HIRAYAMA ,  Douglas Robert CARY ,  Koji ONO ,  Naoki IWAMURA

IPC: C07D513/04

CPC classification number: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

Abstract translation: （其中符号如说明书中所定义）或其盐。

公开(公告)号：US20230293522A1

公开(公告)日：2023-09-21

申请号：US18045748

申请日：2022-10-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Matthew O. DUFFEY ,  Dylan ENGLAND ,  Brian Scott FREEZE ,  Zhigen HU ,  Steven LANGSTON ,  Charles MCINTYRE ,  Hirotake MIZUTANI ,  Koji ONO ,  He XU

IPC: A61K31/506 ,  C07D409/14 ,  C07D409/06 ,  C07D405/06 ,  C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/052 ,  C07D513/04 ,  C07D498/04 ,  C07D493/04 ,  A61K31/505 ,  A61K31/34 ,  C07F9/535 ,  C07F9/54 ,  C07F9/6558 ,  C07F9/655

CPC classification number: A61K31/506 ,  C07D409/14 ,  C07D409/06 ,  C07D405/06 ,  C07D471/04 ,  C07D495/04 ,  C07D487/04 ,  C07D491/052 ,  C07D513/04 ,  C07D498/04 ,  C07D493/04 ,  A61K31/505 ,  A61K31/34 ,  C07F9/5352 ,  C07F9/5442 ,  C07F9/65586 ,  C07F9/65522

Abstract: Disclosed are chemical entities which are compounds of formula (I):




or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

公开(公告)号：US20210115067A1

公开(公告)日：2021-04-22

申请号：US17130297

申请日：2020-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi KAWAKITA ,  Takuto KOJIMA ,  Noriyuki NII ,  Yoshiteru ITO ,  Nobuki SAKAUCHI ,  Hiroshi BANNO ,  Xin LIU ,  Koji ONO ,  Keisuke IMAMURA ,  Shinichi IMAMURA

IPC: C07D519/00 ,  A61K31/444 ,  A61K31/53 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/4985 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

公开(公告)号：US20170015654A1

公开(公告)日：2017-01-19

申请号：US15124932

申请日：2015-03-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Keisuke IMAMURA ,  Naoki TOMITA ,  Yoshiteru ITO ,  Koji ONO ,  Hironobu MAEZAKI ,  Noriyuki NII

IPC: C07D413/14 ,  C07D417/14 ,  C07D403/14 ,  C07D413/04 ,  C07D401/14

CPC classification number: C07D413/14 ,  A61K9/0019 ,  A61K9/1617 ,  A61K9/19 ,  A61K9/2013 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D417/14

Abstract: The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof.

Abstract translation: （其中每个符号如本说明书中所定义）或其盐。

公开(公告)号：US20210363130A1

公开(公告)日：2021-11-25

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D405/12 ,  C07D213/84 ,  C07D403/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.